NASDAQ: MEIP - MEI Pharma, Inc.

Rentabilidad a seis meses: -12.86%
Sector: Healthcare

Calendario de promoción MEI Pharma, Inc.

Horario avanzado gráfico sencillo
Financial Markets by TradingView

Acerca de la empresa

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies.

más detalles
It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Añadir a la lista de comparación
Añadir a la lista de vigilancia
Añadir al portafolio
Añadir aviso de precio

EBITDA -0.0738
EV/EBITDA -2.32
IPO date 2003-12-19
ISIN US55279B2025
Industry Biotechnology
P/BV 3.78
P/E 1.04
P/S 36.82
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 0.0049
Див.доход ао 0
Дивиденд ао 1.75
Сайт https://www.meipharma.com
Цена ао 3.86
Число акций ао 0.00666 млрд
Cambio de precio por día: +2.52% (2.38)
Cambio de precio por semana.: -2.4% (2.5)
Cambio de precio por mes: -12.86% (2.8)
Cambio de precio en 3 meses.: -15.86% (2.9)
Cambio de precio en seis meses: -12.86% (2.8)
Cambio de precio por año: -57.93% (5.8)
Cambio de precio en 3 años.: +0.8264% (2.42)
Cambio de precio en 5 años.: +31.89% (1.85)
Cambio de precio en 10 años.: 0% (2.44)
Cambio de precio desde principios de año.: +3.39% (2.36)
Todos los parámetros

Subestimación

Nombre Significado Calificación
P/S 0.2837 10
P/BV 0.561 10
P/E 1.04 10
EV/EBITDA 0.5617 10
Total: 10

Eficiencia

Nombre Significado Calificación
ROA, % 21.92 7
ROE, % 61.68 10
Total: 7.5

Dividendos

Nombre Significado Calificación
Div yield, % 0 0
DSI 0.5 5
Total: 2.35

Deber

Nombre Significado Calificación
Debt/EBITDA 0.4825 10
Total: 9.6

Impulso de crecimiento

Nombre Significado Calificación
Rentabilidad Revenue, % 125.94 10
Rentabilidad Ebitda, % -1748.75 0
Rentabilidad EPS, % -126.42 0
Total: 2
Más detalles

Dividendo, % Dividendo Con base en los resultados del período. comprar antes Fecha de cierre del registro Pago antes
45.34% 1.75 III кв. 2023 14.11.2023 16.11.2023 01.12.2023
Más detalles

Instituciones Volumen Compartir, %
Anson Funds Management LP 1093188 16.41
Cable Car Capital LLC 611440 9.18
Vanguard Group Inc 389807 5.85
Tang Capital Management, LLC 326084 4.89
Acadian Asset Management. LLC 225391 3.38
Renaissance Technologies, LLC 150892 2.26
Blackrock Inc. 83318 1.25
Carlson Capital. L.P. 74000 1.11
Geode Capital Management, LLC 51616 0.77
Macquarie Group Limited 29999 0.45



Supervisor Título profesional Pago año de nacimiento
Mr. Justin J. File Acting CEO, CFO & Corporate Secretary N/A 1970 (55 años)
Ms. Yomara Gomez-Naiden Senior Vice President of Operations & Quality N/A
Ms. Nicole Chyoko Iida Vice President of Legal Affairs N/A
Ms. Anne Frese Chief People Officer N/A
Dr. Robert D. Mass Strategic Advisor 201.68k 1954 (71 año)
Mr. David A. Walsey J.D., L.L.M. Senior Vice President of Corporate Affairs N/A

DIRECCIÓN: United States, San Diego. CA, 11455 El Camino Real - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.meipharma.com